Skip to main content

Table 1 Patient, disease, and transplant characteristics

From: Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

 

FT

TBF

FLAMSA

p

Number (total, 856)

113

112

631

 

Follow-up for survivors (months), median (95% CI)

53 (10–34)

16 (3–10)

53 (95% CI 4–35)

< 0.001

Age of patient at HSCT (years), median (range) (IQR)

58 (21–76) (47–64)

52.1 (24.4–70.1) (38.1–61)

51.5 (18.1–76) (41.9–59.9)

0.001

Age of patient at HSCT (categorical), n (%)

   

0.028

 < 50 years

35 (31%)

46 (41%)

280 (44%)

 

 ≥ 50 years

78 (69%)

66 (59%)

351 (56%)

 

Gender of patient, n (%)

   

0.09

 Male

66 (59%)

71 (63%)

336 (53%)

 

 Female

47 (41%)

41 (37%)

295 (47%)

 

Karnofsky performance status at SCT, n (%)

   

0.7

 KPS < 80

14 (13%)

12 (11%)

61 (10%)

 

 KPS ≥ 80

95 (87%)

95 (89%)

523 (90%)

 

 Missing

4

5

47

 

Cytogenetics, n (%)

   

0.6

 Favorable

7 (6%)

2 (2%)

19 (3%)

 

 Intermediate

37 (33%)

38 (34%)

228 (36%)

 

 Adverse

20 (18%)

19 (17%)

112 (18%)

 

 Missing

49 (43%)

53 (47%)

272 (43%)

 

Disease status, n (%)

   

0.2

 Primary induction failure

73 (64%)

59 (53%)

344 (55%)

 

 First relapse

30 (27%)

44 (39%)

241 (38%)

 

 Second relapse

10 (9%)

9 (8%)

46 (7%)

 

Year of transplant, median (range)

2011 (2005–2016)

2015 (2007–2016)

2010 (2005–2016)

< 0.001

Donor, n (%)

   

0.06

 MSD

56 (49%)

54 (48%)

252 (40%)

 

 UD 10/10

44 (39%)

35 (31%)

268 (42%)

 

 UD 9/10

13 (12%)

23 (21%)

111 (18%)

 

Donor/recipient sex mismatch, n (%)

   

0.8

 F to M

19 (18%)

21 (19%)

124 (20%)

 

 No F to M

87 (82%)

91 (81%)

490 (80%)

 

Stem cell source, n (%)

   

< 0.001

 BM

4 (4%)

19 (17%)

15 (2%)

 

 PBSCs

109 (96%)

93 (83%)

616 (98%)

 

CMV donor/recipient, n (%)

   

< 0.001

 Donor−/Recipient−

22 (21%)

13 (12%)

167 (27%)

 

 Donor+/Recipient−

9 (8%)

8 (7%)

76 (12%)

 

 Donor−/Recipient+

21 (19%)

25 (23%)

140 (23%)

 

 Donor+/Recipient+

57 (52%)

61 (58%)

229 (37%)

 

ATG used, n (%)

   

< 0.001

 No

69 (61%)

46 (42%)

73 (12%)

 

 Yes

44 (39%)

64 (58%)

554 (88%)

 
  1. Some percentages do not add up to 100% because of rounding
  2. ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, FLAMSA fludarabine, intermediate dose Ara-C, amsacrine, total body irradiation, cyclophosphamide sequential regimen, KPS Karnofsky performance status, FT fludarabine-treosulfan, GVHD graft-versus-host disease, LFS leukemia-free survival, MAC myeloablative, MSD matched sibling donor, NRM non-relapse mortality, OS overall survival, PBSCs peripheral blood stem cells, RI relapse incidence, TBF thiotepa-busulfan-fludarabine, TBI total-body irradiation, UD unrelated donor